A week after Illumina announced its new high-throughput sequencing platform, the HiSeq X Ten, the New York Genome Center said it has purchased one of the systems.
Bob Darnell, NYGC's CEO, president, and scientific director, told In Sequence that the decision to acquire the HiSeq X Ten resulted from the necessity to move from exome sequencing to whole-genome sequencing in order to be able to capture disease-causing mutations that would otherwise be missed. "The future is being more comprehensive," he said.
The center expects the new instruments to arrive by the end of March, according to Darnell. Initially, they will be mostly used for work by members of the New York Genome Center, but longer term the center plans to engage in academic collaborations to make full use of the system's capacity, he said.
Each of the 10 units can generate about 1.8 terabases of data in under three days, or 15 human genomes at high coverage, so the theoretical output of the system is more than 18,000 genomes per year, at a cost of under $1,000 per genome, according to Illumina.
Illumina sells the instrument in sets of 10 for a total of $10 million, and customers are only permitted to use the HiSeq X Ten for human whole-genome sequencing.
Other than the NYGC, the first customers are the Broad Institute, the Garvan Institute in Australia, and Macrogen in Korea.
Illumina said it can ship the HiSeq X Ten to up to five customers this year, though it might be able to increase its manufacturing capacity to accommodate more customers.